Detection of circulating DNA methylated BCAT1 and IKZF1 in pancreatic adenocarcinoma

Jean Winter, Lorraine Sheehan-Hennessy, Susanne Pedersen, Graeme P. Young AM FTSE FAHMS AGAF, Erin Symonds

Research output: Contribution to journalMeeting Abstractpeer-review


Pancreatic adenocarcinoma patients have poor survival outcomes and there are no non-invasive tests to aid diagnosis or therapy. Detection of circulating tumour DNA (ctDNA) methylated for BCAT1 and/or IKZF1 is over 60% sensitive for colorectal adenocarcinoma. Both pancreatic and colorectal adenocarcinomas are of endodermal origin, therefore, these methylated biomarkers might also have utility in detecting pancreatic cancer. The aim of this study was to investigate whether individuals with pancreatic adenocarcinoma have detectable methylated BCAT1 and IKZF1 DNA in circulation.
Original languageEnglish
Number of pages2
JournalJournal of Clinical Oncology
Issue number4 suppl
Publication statusPublished - 1 Feb 2022
Event2022 ASCO Gastrointestinal Cancers Symposium - San Francisco, United States
Duration: 20 Jan 202222 Jan 2022


  • BCAT1
  • IKZF1
  • pancreatic adenocarcinoma
  • circulating tumor DNA
  • biomarkers
  • ctDNA
  • pancreatic cancer


Dive into the research topics of 'Detection of circulating DNA methylated BCAT1 and IKZF1 in pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this